A European study in The Lancet found that about one in eight HIV-positive patients younger than 16 becomes resistant to three main antiviral classes, including protease inhibitors, within five years of starting them. Researchers learned that those who begin therapy at an older age have a greater risk of triple-class virological failure. The higher rate of multidrug resistance in young patients might be associated with lower medication adherence, an expert said.

Related Summaries